AdvaMed Wants Across-The-Board Risk-Based Regulation For Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Under an AdvaMed plan for expanding FDA regulation of diagnostic tests, tests that consist of new or unproven biomarkers on new technology platforms would likely require a pre-market approval application